Rosiglitazone Ameliorates Diabetic Nephropathy by Reducing the Expression of Chemerin and ChemR23 in the Kidney of Streptozotocin-Induced Diabetic Rats

被引：0
作者：
Wenchao Hu
Qian Yu
Jie Zhang
Demin Liu
机构：
[1] Tianjin Medical University,Department of Metabolism, General Hospital
[2] Tianjin Medical University,Department of Laboratory, Metabolic Disease Hospital
来源：
Inflammation | 2012年 / 35卷
关键词：
chemerin; ChemR23; diabetic nephropathy; rosiglitazone; pioglitazone; inflammation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Chemerin is shown to be associated with inflammation which is involved in the pathogenesis of diabetic nephropathy. This study aims to determine whether rosiglitazone and pioglitazone ameliorate renal function through an effect on the expression of chemerin and ChemR23 in streptozotocin-induced diabetic rats. The rats were randomized to control, diabetic, rosiglitazone-, and pioglitazone-treated groups. The expression level of chemerin and ChemR23 in the renal tissues was significantly elevated in the diabetic group compared with the control group. Rosiglitazone inhibited the overexpression of chemerin and ChemR23, while pioglitazone inhibited the overexpression of ChemR23 in the kidney of diabetic rats. In addition, chemerin expression level was positively correlated with transforming growth factor-β1, connective tissue growth factor, tumor necrosis factor-α, and intracellular cell adhesion molecule-1 expression in diabetic rats. Rosiglitazone ameliorates diabetic nephropathy by reducing the expression of chemerin and ChemR23 in diabetic rats.
引用
收藏
页码：1287 / 1293
页数：6
相关论文
共 197 条
[11]  
Qureshi AR(2009)Rosiglitazone protects diabetic rats against kidney disease through the suppression of renal moncyte chemoattractant protein-1 expression Journal of Diabetes and its Complications 23 124-129
[12]  
Anderstam B(2008)Rosiglitazone improves insulin sensitivity with increased serum leptin levels in patients with type 2 diabetes mellitus Diabetes Research and Clinical Practice 81 42-49
[13]  
Heimbürger O(2007)Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: A randomized placebo-controlled study European Journal of Endocrinology 156 263-269
[14]  
Bárány P(2009)Low-dose pioglitazone increases serum high molecular weight adiponectin and improves glycemic control in Japanese patients with poorly controlled type 2 diabetes Diabetes Research and Clinical Practice 85 147-152
[15]  
Lindholm B(2008)Impact of rosiglitazone on visfatin and adiponectin plasma concentrations in patients with type 2 diabetes and coronary artery disease Clinical Laboratory 54 237-241
[16]  
Stenvinkel P(2007)Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism Journal of Biological Chemistry 282 28175-28188
[17]  
Axelsson J(2008)Chemerin is an independent marker of the metabolic syndrome in a Caucasian population–a pilot study Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 152 217-221
[18]  
Hu W(2009)Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population Journal of Clinical Endocrinology and Metabolism 94 3085-3088
[19]  
Feng P(2011)Thiazolidinediones plus metformin association on body weight in patients with type 2 diabetes Diabetes Research and Clinical Practice 91 265-270
[20]  
Lehrke M(2010)Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: A meta-analysis American Journal of Kidney Diseases 55 835-847
12345678910